A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

NCT06006598 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-05-14

No results posted yet for this study

Summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 1584862 in healthy male subjects following administration of multiple rising doses.

Conditions

  • Healthy

Interventions

DRUG

BI 1584862

BI 1584862

DRUG

Placebo matching BI 1584862

Placebo matching BI 1584862

DRUG

midazolam

midazolam

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2024-05-05
Completion
2024-05-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06006598 on ClinicalTrials.gov